Liraglutide significantly improves hepatic steatosis and metabolic parameters among patients with MASLD — without meaningful reductions in liver stiffness.

Weight loss jabs could be used to treat Alzheimer’s disease after a study found the drug may slow cognitive decline.

Some weight-loss and diabetes drugs can treat obesity when combined with exercise, a healthy diet, and counseling, according to WHO's first guidance on these medicines. The recommendations come amid ...

The World Health Organization (WHO) has issued its first-ever global guideline recommending that GLP-1 medicines (like those ...

With no evidence base to draw upon, clinicians are sharing strategies to help patients stop taking the new weight-loss drugs ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide, liraglutide, and tirzepatide are widely prescribed ...

Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, researchers aren’t giving up yet.

GLP-1 receptor agonists affect sexual function differently across individuals and influencing libido and hormone levels in ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow ...

Pfizer (NYSE: PFE) and Teva Pharmaceutical Industries (NYSE: TEVA) just reported third-quarter earnings that reveal two ...

The WHO released new guidance on GLP-1 medications for adults with obesity, recommending their long-term, continuous use when ...

Brain scans in patients revealed the drug slowed brain volume loss by around half compared to the placebo. A weight-loss jab ...